Medistem CEO co-authors MRI study in sheep.
San Diego, Calif-based Medistem Inc. (P1NKSHEETS: MEDS) said on December 13 that its CEO Thomas Ichim co-authored a research project using MRI to assess brain changes in sheep infected with scrapie (the sheep form of mad cow disease) before symptoms of the fatal brain disease appear.
The study, whose senior author was Dr. Joel Stutman, compared 37 sheep that were positive for the infectious protein associated with scrapie, called PrPSc, to 80 sheep that had no evidence of the disease-causing protein. It was found that all sheep possessing the protein, whether symptomatic or non-symptomatic, exhibited a unique change in the anatomy of the brain as detected by MRI. Specifically, a greater ventricle to cerebrum area ratio was found in MRI images of infected sheep compared to healthy sheep.
The project integrated computer-based image analysis techniques with molecular diagnostics to demonstrate that in sheep with scrapie specific MRI changes can be indicative of neurodegeneration before symptoms appear.
"One of the major findings in the published stem cell clinical trials has been that some patients respond extremely well, while others do not," Medistem President Vladimir Bogin, M.D. "Medistem believes that development of disease-assessing techniques such as the one reported, will allow for better selection of patients that would respond to stem cell-based interventions."
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Briefly Noted|
|Publication:||Stem Cell Business News|
|Date:||Dec 20, 2010|
|Previous Article:||Stem Cell Thera awarded U.S. patent relating to NTx-265.|
|Next Article:||Canadian agency asks for more information on prochymal as GvHD treatment.|